A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia

Summary

The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.

Timeline

Start

2016-06-16

Primary completion

2018-07-02

Completion

2018-07-02

Outcome

Missed primary endpoint

Stopped: “Low likelihood of identifying a statistically significant treatment effect.”

registry analysis (superiority test); 3 mg LY3202626 vs Placebo; p = 0.418; ANCOVA NCT02791191 ↗

registry analysis (superiority test); 12 mg LY3202626 vs Placebo; p = 0.231; ANCOVA NCT02791191 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LY3202626	Unknown	3 mg	Oral
Subject	LY3202626	Unknown	12 mg	Oral

Indications